Outcome of Clareon Toric Intraocular Lens Implantation in Cataract Patients

Retrospective chart review of Clareon Toric Intraocular Lens Outcomes in Patients Who Underwent Routine, Uncomplicated Cataract Surgery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12624000221550

Enrollment

161

Registered

2024-03-06

Start date

2024-01-25

Completion date

2024-01-25

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The Clareon Monofocal Toric intraocular lens (IOL) is a relatively recently released device from Alcon. It is an IOL based on the successful AcrySof IQ Aspheric Monofocal Toric format with modifications made to the material and edge design aimed at improving optical clarity, rotational stability, and optical side effects. The purpose of this study was to comprehensively assess the safety and effectiveness of the Clareon Monofocal Toric IOLs from those who received the Clareon Monofocal Toric IOLs implantation following cataract surgery.

Interventions

No intervention/exposure is being performed. This is a retrospective chart review of visual and intraocular lens performance in patients who underwent routine, uncomplicated cataract surgery between January 2021 and October 2023 by a single surgeon.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Eyes undergoing routine cataract surgery requiring implantation of a Clareon monofocal toric intraocular lens.

Exclusion criteria

Previous ocular surgery, ocular pathology limiting visual outcome, other health issues limiting ability to attain subjective refraction such as dementia.

Outcome results